Abstract Background With the increasing number of effective therapies for inflammatory bowel diseases (IBD), determining optimal treatment sequences is challenging. Given the impracticality of conducting randomized head-to-head trials for every comparison, this study assessed whether phase 3 placebo-controlled trials can reliably predict outcomes of published head-to-head studies. Methods Three randomized head-to-head trials without placebo arms were analyzed alongside their corresponding phase 3 placebo-controlled trials. Effect sizes for clinical and endoscopic endpoints were extracted for comparison. Results In the VARSITY trial, vedolizumab achieved an 8.8% higher clinical remission rate than adalimumab at week 52 in patients with ulcerative colitis. Placebo-controlled studies estimated a 17.3% advantage for vedolizumab; however, differences in trial design and patient populations between GEMINI-1 and ULTRA-2 limit the robustness of this indirect comparison. In Crohn’s disease, indirect comparisons of IM-UNITI, CLASSIC-II, and CHARM suggested an 11.6–18.6% higher efficacy for adalimumab compared with ustekinumab in biologic-naïve patients, yet the SEAVUE head-to-head trial found no significant difference at week 52. Most recently, the SEQUENCE trial demonstrated a + 15.6% superiority of risankizumab over ustekinumab in endoscopic remission at week 48 among bio-exposed Crohn’s disease patients, whereas indirect comparisons between FORTIFY and IM-UNITI were confounded by clinically relevant population differences. Conclusion Significant heterogeneity in trial design, populations and outcome reporting limits the predictive value of placebo-controlled trials. Randomized head-to-head trials remain essential for optimizing IBD therapeutic strategies.
Chkolnaia et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: